Ginkgo Bioworks Holdings, Inc. Class A (DNA)

Over the past six months, Ginkgo Bioworks Holdings, Inc.'s stock price has underperformed the S&P500 Index. Key events include the Q1 2026 earnings report with a revenue decrease but better-than-expected EPS, the divestiture of the Biosecurity business, a strategic pivot to AI-driven autonomous labs, analyst sentiment with a 'Reduce' rating, insider selling, and high stock price volatility.

No explicit information regarding demand seasonality for Ginkgo Bioworks Holdings, Inc.'s products and services was found. The company's business model does not inherently suggest strong seasonal fluctuations, but specific data is not available.

Ginkgo Bioworks Holdings, Inc. is a biotechnology company specializing in cell programming and genetic engineering for industrial applications across various markets. It operates through Cell Engineering, providing cell engineering solutions, and previously Biosecurity, which was divested in April 2026. The company is in the Pharmaceuticals & Biotech sector, specifically Life Sciences Tools and Services.

Ginkgo Bioworks Holdings, Inc. is headquartered in Boston, Massachusetts, U.S. The company has expanded its operational footprint with additional laboratories and foundry facilities located in the United States and Europe.

Information detailing events that have affected Ginkgo Bioworks Holdings, Inc.'s brand reputation in the past year is not readily available. In 2021, the company faced fraud allegations and a shareholder lawsuit, prompting an inquiry by the United States Department of Justice. The recent strategic pivot towards AI-driven autonomous labs and the divestiture of its Biosecurity business could impact its reputation in the long term.

The ownership structure of Ginkgo Bioworks Holdings (DNA) stock is a mix of institutional, retail, and individual investors. Approximately 33.93% of the company's stock is owned by Institutional Investors, 3.43% by Insiders, and 62.64% by Public Companies and Individual Investors. Major institutional shareholders include Viking Global Investors Lp, BlackRock, Inc., Vanguard Group Inc, Baillie Gifford & Co, and State Street Corp. CEO Jason Kelly owns 3.8% of the company's shares.